A股異動 | 萊茵生物(002166.SZ)漲停 美國工業大麻建設項目預計6月30日前正式量產
格隆匯3月21日丨萊茵生物(002166.SZ)午後直線拉昇至漲停,現報9元,暫成交3億元,最新市值50億元。萊茵生物今日午間公佈,公司預計美國工業大麻建設項目將於2022年6月30日前達成正式量產。近日,公司孫公司HempRise與美國一家工業大麻產品提供商(A公司)簽訂了一份《受託加工意向協議》,計劃2022年8月至12月期間,A公司將委託 Hemprise 加工50萬鎊的工業大麻原料,Hemprise根據其規格要求將原料加工成高純度CBD晶體或粉末提供給A公司。初步估計本協議的加工費金額將超過255萬美元,最高將不超過570萬美元。此外,萊茵生物近日披露投資者關係活動記錄表公吿,公司對目前主推大單品天然甜味劑、工業大麻提取、茶葉提取的未來發展空間與增速充滿信心,預計未來三年營收年均增速目標為30%以上。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.